Valneva SE (VLA):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(SWOT20MY1664)
◆英語タイトル:Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1664
◆発行会社(リサーチ会社):GlobalData
◆発行日:2020年4月
◆ページ数:57
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Valneva SE (VLA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Valneva SE (Valneva) is a biotechnology company that develops lifesaving vaccines against infectious diseases and cancer. The company’s products include a vaccine indicated for the prevention of Japanese encephalitis; and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of lyme, chikungunya, zika virus and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline vaccine candidates and to distribute its products. The company sells its products in the Americas, Asia Pacific, Europe and the Middle East. It operates in Austria, Sweden, the UK, France, the US and Canada. Valneva is headquartered in Saint-Herblain, France.

Valneva SE Key Recent Developments

Mar 24,2020 Valneva provides business update on COVID-19 situation
Feb 03,2020 Valneva announces new $85 million financing arrangement with leading US healthcare funds Deerfield and OrbiMed
Jan 09,2020 Valneva Expands its commercial operations with the opening of its French commercial office
Dec 20,2019 Valneva completes delisting from the Vienna Stock Exchange

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Valneva SE – Key Facts
Valneva SE – Key Employees
Valneva SE – Key Employee Biographies
Valneva SE – Major Products and Services
Valneva SE – History
Valneva SE – Company Statement
Valneva SE – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Valneva SE – Business Description
Product Category: Dukoral
Overview
Performance
Key Stats
Product Category: Ixiaro/Jespect
Overview
Performance
Key Stats
Product Category: Other
Performance
Product Category: Revenues from Collaborations, Licensing and Services
Performance
Product Category: Third Party Products
Performance
Product Category: Total Product sales
Performance
Product Category: Commercialized Vaccines
Overview
Performance
Product Category: Technologies and Services
Overview
Performance
Product Category: Vaccine Candidates
Overview
Performance
Geographical Segment: Austria
Performance
Geographical Segment: Canada
Capital Expenditure
Geographical Segment: Germany
Performance
Geographical Segment: Nordics
Capital Expenditure
Geographical Segment: Other Europe
Performance
Geographical Segment: Other markets
Performance
Geographical Segment: Switzerland
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
Valneva SE – Corporate Strategy
Valneva SE – SWOT Analysis
SWOT Analysis – Overview
Valneva SE – Strengths
Valneva SE – Weaknesses
Valneva SE – Opportunities
Valneva SE – Threats
Valneva SE – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Valneva SE, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 24, 2020: Valneva provides business update on COVID-19 situation
Feb 03, 2020: Valneva announces new $85 million financing arrangement with leading US healthcare funds Deerfield and OrbiMed
Jan 09, 2020: Valneva Expands its commercial operations with the opening of its French commercial office
Dec 20, 2019: Valneva completes delisting from the Vienna Stock Exchange
Dec 12, 2019: Valneva appoints MVM Partner Thomas Casdagli to its supervisory board
Dec 09, 2019: Valneva appoints Renowned Vaccinologists Stanley Plotkin and Anna Durbin to its Scientific Advisory Board
Nov 13, 2019: Valneva announces appointments of two leading vaccine experts to its scientific advisory board
Oct 31, 2019: Valneva raises product sales guidance following strong nine-month results and R&D execution
Sep 19, 2019: Valneva Confirms Delisting from the Vienna Stock Exchange
Aug 01, 2019: Valneva reports H1 2019 results marked by strong operational performance and major corporate progress
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Valneva SE, Key Facts
Valneva SE, Key Employees
Valneva SE, Key Employee Biographies
Valneva SE, Major Products and Services
Valneva SE, History
Valneva SE, Subsidiaries
Valneva SE, Key Competitors
Valneva SE, Ratios based on current share price
Valneva SE, Annual Ratios
Valneva SE, Annual Ratios (Cont...1)
Valneva SE, Annual Ratios (Cont...2)
Valneva SE, Interim Ratios
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Valneva SE, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Valneva SE, Performance Chart (2015 - 2019)
Valneva SE, Ratio Charts
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Valneva SE (VLA):企業の財務・戦略的SWOT分析(Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆